Key result
Low-molecular-weight heparins reduce venous thromboembolism in cancer patients and may inhibit tumor growth, though direct anticancer effects without thrombosis remain to be clinically documented.
Why the study?
Do low-molecular-weight heparins reduce venous thromboembolism and improve survival in patients with cancer?
Population
Patients with cancer and thromboembolic disorders or at risk of venous thromboembolism
Comparison
Low-molecular-weight heparins (LMWHs) vs Unfractionated heparin (UFH)
Design
Review
Authors
Loading...
LMWHs remain appropriate for VTE prevention in cancer; leaves open direct anticancer effects independent of thrombosis.
Do low-molecular-weight heparins reduce venous thromboembolism and improve survival in patients with cancer?
LMWHs provide effective thromboprophylaxis in cancer patients and may offer survival benefits by inhibiting tumor growth and metastasis, though direct anticancer effects require further clinical documentation.
Shaker A. Mousa (2004) conducted a review in Cancer and thrombosis. Low-molecular-weight heparins (LMWHs) vs. Unfractionated heparin (UFH) was evaluated. Low-molecular-weight heparins reduce venous thromboembolism in cancer patients and may inhibit tumor growth, though direct anticancer effects without thrombosis remain to be clinically documented.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: